Ideaya Biosciences Inc (IDYA)

$42.18

+0.69

(+1.66%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Ideaya Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 8.03M → 3.92M (in $), with an average decrease of 51.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -27.44M → -33.95M (in $), with an average decrease of 23.7% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.3% return, outperforming this stock by 108.9%

Performance

  • $42.04
    $42.96
    $42.18
    downward going graph

    0.33%

    Downside

    Day's Volatility :2.14%

    Upside

    1.82%

    downward going graph
  • $18.50
    $47.74
    $42.18
    downward going graph

    56.14%

    Downside

    52 Weeks Volatility :61.25%

    Upside

    11.65%

    downward going graph

Returns

PeriodIdeaya Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-3.23%
-1.1%
0.0%
6 Months
45.8%
10.5%
0.0%
1 Year
121.19%
5.4%
0.5%
3 Years
123.41%
14.4%
-21.1%

Highlights

Market Capitalization
2.9B
Book Value
$9.55
Earnings Per Share (EPS)
-1.96
Wall Street Target Price
53.0
Profit Margin
0.0%
Operating Margin TTM
-1068.77%
Return On Assets TTM
-16.2%
Return On Equity TTM
-23.28%
Revenue TTM
23.4M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
-2.5%
Gross Profit TTM
-38.6M
EBITDA
-132.0M
Diluted Eps TTM
-1.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.19
EPS Estimate Next Year
-1.83
EPS Estimate Current Quarter
-0.47
EPS Estimate Next Quarter
-0.57

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Ideaya Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 25.65%

Current $42.18
Target $53.00

Technicals Summary

Sell

Neutral

Buy

Ideaya Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ideaya Biosciences Inc
Ideaya Biosciences Inc
-0.78%
45.8%
121.19%
123.41%
276.94%
Moderna, Inc.
Moderna, Inc.
21.5%
73.44%
-8.79%
-23.24%
361.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.52%
14.97%
25.57%
98.37%
178.01%
Novo Nordisk A/s
Novo Nordisk A/s
-2.23%
21.74%
50.76%
232.25%
415.39%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.37%
3.97%
15.22%
87.53%
129.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ideaya Biosciences Inc
Ideaya Biosciences Inc
NA
NA
NA
-2.19
-0.23
-0.16
NA
9.55
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ideaya Biosciences Inc
Ideaya Biosciences Inc
Buy
$2.9B
276.94%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
361.25%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
178.01%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
415.39%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
129.5%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    7.27%

  • Bvf Inc

    7.07%

  • Federated Hermes Inc

    5.19%

  • T. Rowe Price Associates, Inc.

    4.77%

  • HHG PLC

    4.75%

  • Vanguard Group Inc

    4.65%

Corporate Announcements

  • Ideaya Biosciences Inc Earnings

    Ideaya Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.

Organization
Ideaya Biosciences Inc
Employees
124
CEO
Mr. Yujiro S. Hata
Industry
Biotechnology

Discover More

FAQs